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O B J E C T I V E S The objective of this study was to perform a systematic review and meta-analysis of
the predictive value of late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) for future
cardiovascular events and death in hypertrophic cardiomyopathy (HCM).
B A C KG ROUND The utility of LGE for detecting myocardial ﬁbrosis is well established. The
prognostic value of LGE in HCM has been described in several studies, but controversy exists given the
limited power of these studies to predict future events.
METHOD S We searched multiple databases including PubMed for studies of LGE in HCM that
reported selected clinical outcomes (cardiovascular mortality, sudden cardiac death [SCD], aborted SCD,
and heart failure death). We performed a systematic review of the literature and meta-analysis to
determine pooled odds ratios for these clinical events.
R E S U L T S Four studies evaluated 1,063 patients over an average follow-up of 3.1 years. The pooled
prevalence of LGE was 60%. The pooled odds ratios (OR) demonstrate that LGE by CMR correlated with
cardiac death (pooled OR: 2.92, 95% conﬁdence interval [CI]: 1.01 to 8.42; p  0.047), heart failure death
(pooled OR: 5.68, 95% CI: 1.04 to 31.07; p 0.045), and all-cause mortality (pooled OR: 4.46, 95% CI: 1.53
to 13.01; p  0.006), and showed a trend toward signiﬁcance for predicting sudden death/aborted
sudden death (pooled OR: 2.39, 95% CI: 0.87 to 6.58; p  0.091).
CONC L U S I O N S Late gadolinium enhancement by CMR has prognostic value in predicting
adverse cardiovascular events among HCM patients. There are signiﬁcant relationships between LGE and
cardiovascular mortality, heart failure death, and all-cause mortality in HCM. Additionally, LGE and
SCD/aborted SCD displayed a trend toward signiﬁcance. The assessment of LGE by CMR has the
potential to provide important information to improve risk stratiﬁcation in HCM in clinical
practice. (J Am Coll Cardiol Img 2012;5:370–7) © 2012 by the American College of Cardiology
Foundation
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371ypertrophic cardiomyopathy (HCM) is the
most common inherited cardiovascular dis-
ease that is characterized by substantial
heterogeneity with respect to presentation,
henotypic expression, clinical course, and overall
rognosis (1–3) Although HCM is the leading
ause of sudden death (SCD) in young people, it
as a diverse phenotypic spectrum such that the
linical presentation can occur during any phase of
ife, and the vast majority of HCM patients with
CD have few to no clinical symptoms (1). In
eneral, HCM confers an annual mortality rate of
bout 1%, but a subset of roughly 10% to 20% of
atients have higher mortality or morbidity due to
omplications arising from SCD (perhaps as high as
% annually), progressive heart failure (HF), and
trial fibrillation complicated by embolic stroke (1).
Device therapy with implantable cardioverter-
efibrillators (ICD) has been shown to be an
xtremely effective intervention for primary preven-
ion of sudden death in patients with HCM (4).
here are 5 clinically accepted high-risk factors for
CD that may justify primary prevention with
CD: 1) a family history of 2 or more premature
udden deaths; 2) extreme left ventricular hypertro-
hy (30 mm); 3) unexplained syncope in young
atients; 4) nonsustained ventricular tachycardia
NSVT) on Holter monitoring in patients 30
ears of age; and 5) an abnormal blood pressure
esponse during upright exercise (4,5). However, in
large HCM ICD registry, only 13% of patients
ith prophylactic primary prevention devices im-
lanted for high-risk features had an appropriate
ischarge for ventricular tachycardia or ventricular
brillation, whereas 25% of these patients had
nappropriate ICD shocks (6). Furthermore, the
isk of appropriate ICD discharge was not signifi-
antly different for 1, 2, or 3 of the traditional
linical risk factors (6). This highlights the impor-
ance of improved methods for SCD risk stratifica-
ion in HCM patients.
Another substantial complication of HCM is pro-
ressive HF, as roughly 15% to 20% of HCM patients
ith heart failure have marked symptom progression
New York Heart Association [NYHA] functional
lasses III and IV) (1). Determining which HCM
atients are at a higher risk for the development and
rogression of HF could identify those who stand
o benefit from more aggressive HF medical therapy
han currently indicated as well as provide prognos-
ic information regarding HF death.
Cardiac magnetic resonance (CMR) is emerging
s a powerful tool for the diagnosis and risk strat-fication in HCM. It is widely accepted as a gold
tandard method for assessment of myocardial
unction as well as left ventricular (LV) mass, which
as been shown to be a sensitive predictor of
dverse outcomes in HCM (7). As myocardial
brosis may provide the underlying arrhythmogenic
ubstrate in HCM, there has been significant inter-
st in using late gadolinium enhancement (LGE) to
valuate myocardial fibrosis. Multiple studies have
emonstrated a high prevalence of LGE, predom-
nantly in a patchy, multifocal mid-wall distribution
n regions of hypertrophy (8,9); and LGE has been
hown to be associated with NSVT as well as with
ther risk factors for SCD (9–12). Furthermore,
he presence of LGE has been shown to be a
arker of adverse outcomes in multiple
onischemic cardiomyopathies (13,14).
nly recently have studies emerged eval-
ating LGE for the prediction of end-
oints of cardiovascular death and SCD in
CM; however, these recent studies have
een limited in size and demonstrate dif-
ering results (15–18). The objective of
his meta-analysis is to determine the
ssociation of LGE by CMR in patients
ith HCM for the prediction of cardiac
ortality, SCD/aborted SCD, HF death,
nd all-cause mortality. That could poten-
ially identify patients who are at risk for
CD who may benefit from prophylactic
CD therapy, as well as providing prog-
ostic information for predicting HCM
eath.
M E T H O D S
Data sources. We searched PubMed/
MEDLINE, the Cochrane Database of
Systemic Reviews, Cochrane Methodol-
ogy Register, Cochrane Controlled Trials Register,
and the ISI Web of Science to identify studies for
meta-analysis inclusion. We used the text words
and related Medical Subject Headings for hypertro-
phic cardiomyopathy and magnetic resonance im-
aging. There were no language restrictions, as
non-English publications were included in initial
search designs and evaluated.
Study selection. Two physician investigators inde-
pendently conducted the literature search and ex-
traction of relevant titles. The titles and abstract of
potentially relevant studies and review articles were
screened for appropriateness before retrieval of the
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372query on December 15, 2010, produced 592 initial
results (Fig. 1). Of these, 572 were excluded by title
or abstract as unrelated to the scientific question.
Twenty studies were retrieved for detailed evalua-
tion, 3 of which were review articles that were
excluded. Of the 17 potentially appropriate studies,
only 4 studies evaluated the selected endpoints
(cardiac death, SCD, and HF death) in HCM
patients using LGE by CMR. These 4 studies were
then included in the meta-analysis. Only 2 of the
studies reported on all-cause mortality and were
analyzed separately for this endpoint.
Data abstraction and validity assessment. Two phy-
ician investigators independently abstracted data
sing a standardized form. We extracted the fol-
owing demographic data: author, year of publica-
ion, design, follow-up duration, sample size, char-
cteristics of LGE CMR used, age, percentage
ale, NYHA functional class I, NYHA functional
lass II, NYHA functional class III/IV, LVEF
50%, LVEF, wall thickness 30 mm, syncope,
ustained ventricular tachycardia/fibrillation, family
istory of SCD, and LGE status. Clinical outcomes
ncluded the raw events data for all-cause mortality,
ll cardiac deaths, SCD/aborted SCD, SCD, and
F death. When disagreements occurred among
ata extractors, the final decision was made by
onsensus of all authors.
Statistical analysis. All statistical analyses were per-
16 full-text articles excluded, 
for the following reasons:
-3: review articles
-13: did not include data on 
chosen clinical endpoints 
(cardiac death, SCD, aborted 
SCD, and HF death)es included in
tive synthesis 
a-analysis)
l-text articles 
d for eligibility
ords screened
ords identified 
gh database 
earching
572 records excluded 
by screening abstracts
0 additional records 
identified through 
other sources
QUORUM Diagram of Selection Process for Articles Included in
lysis
es met criteria for inclusion; 13 studies were excluded because of
rmation related to the chosen clinical endpoints (cardiac death,
rdiac death [SCD], aborted SCD, and heart failure [HF] death), and
ere excluded because they were review articles.formed using the Comprehensive Meta Analysisprogram (Biostat, Englewood, New Jersey). Data
were analyzed according to the intention-to- treat
principle. The Cochrane Q statistic and I2 statistic
was calculated to assess heterogeneity among the
trials. The Q statistic and I2 statistic failed to
indicate statistical heterogeneity for any endpoint.
The odds ratio (OR) for each study was recalculated
from raw event data. Based upon the lack of
heterogeneity in the studies, we chose to use a
fixed-effects model. A summary OR was calculated
using a fixed-effects model from the OR and the
95% confidence interval (CI) for each endpoint in
each study using Mantel-Haenszel methods. To
assess publication bias, we generated a funnel plot
of the logarithm of effect size and compared it with
the standard error for each trial. A p value 0.05
was considered statistically significant.
R E S U L T S
A focused PubMed literature search only yielded 4
CMR studies with LGE that included data on the
clinical endpoints of cardiovascular mortality, SCD
or aborted SCD, and HF death. The data from
these 4 studies was pooled together (total of 1,063
patients), and the endpoints were reanalyzed
through pooled OR to evaluate the association of
LGE with these endpoints. All 4 studies reported
on SCD, cardiac death, and HF death. Cardiac
death included both SCD and HF death in 3 of the
studies, whereas the study by Maron et al. (18) did
not have any cases of HF death. Aborted SCD was
deemed as appropriate ICD discharge in 1 study,
and 2 studies defined SCD as appropriate ICD
therapies, whereas Bruder et al. (15) incorporated a
broader definition of aborted SCD. Only 2 studies
reported all-cause mortality, and these studies were
analyzed separately for this endpoint. A query of the
LGE techniques utilized in all included studies found
that a 1.5T scanner with 6-mm to 10-mm section
thickness were used to acquire delayed enhancements
images 10 to 15 min after the intravenous adminis-
tration of 0.1 to 0.2 mmol/kg of gadolinium-based
contrast agent using a breath-hold 2-dimensional
segmented inversion-recovery sequence. All acquisi-
tions were consistent with Society for Cardiovascular
Magnetic Resonance published guidelines (19).
Table 1 shows the inclusion and exclusion criteria
and primary endpoints evaluated in each of these
studies. Three of these studies were prospective cohort
studies of HCM patients, whereas the study by
Rubinshtein et al. (17) was a retrospective analysis4 studi
quantita
(met
20 ful
assesse
592 rec
592 rec
throu
s
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373with LGE assessment (15–18). Patients with known
coronary artery disease (CAD) were explicitly ex-
cluded in the studies by Maron et al. (18),
O’Hanlon et al. (16), and Bruder et al. (15). The
study by Rubinshtein et al. (17) included 37 patients
(9%) with known CAD. All studies either specifically
excluded or did not include patients who had under-
gone prior septal ablation or myectomy. Only studies
by Rubinshtein et al. (17) and Bruder et al. (15)
reported all-cause mortality, and the study by Maron
et al. (18) did not specifically report on HF death.
The baseline characteristics from these studies, as
well as the pooled characteristics are shown in
Table 2. Overall, 1,063 patients were included in
the meta-analysis; 64% of the subjects were male,
and the mean age across all of the studies was 52
years. The study by Maron et al. (18) had a younger
mean age of 42 years. Across all studies, 17% of
patients had NYHA functional class III/IV HF;
however, the study by Rubinshtein et al. (17) had a
higher prevalence of severe HF (29%). There was
a high prevalence of LGE in these studies, averag-
ing 60% (range 55% to 67%) of the subjects. Three
of the studies had an average follow-up period of at
least 3.0 years, but the study by Maron et al. (18)
had an average follow-up period of only 1.9 years.
These 4 studies demonstrated differing results
with respect to the primary outcomes (cardiac
death, HF death, SCD, aborted SCD, and all-cause
mortality) evaluated in this meta-analysis. The
study by Maron et al. (18) demonstrated no differ-
Table 1. Summary of Included Studies
First Author (Ref. #) Year Inclu
Maron (18) 2008 HCM patients p
Tufts Medica
Minneapolis
Foundation
Rubinshtein (17) 2010 HCM patients w
CE-MRI at M
O’Hanlon (16) 2010 HCM patients r
CMR at Roya
Hospital
Bruder (15) 2010 Patients with k
suspected H
to Essen and
workup
CAD  coronary artery disease; CE  contrast enhanced; CMR  cardiac
cardioverter-deﬁbrillator; IV  intravenous; LV  left ventricular; MRI  magneence in adverse cardiovascular events per year inpatients with LGE versus patients without LGE
(5.5% vs. 3.3%, p  0.5) (18). The study by
Rubinshtein et al. (17) demonstrated a significant
association between the presence of LGE and a
SCD or aborted SCD events, with all events occur-
ring in patients with LGE (p  0.002) (17). The
study did not specifically analyze cardiovascular
death, but all of the cardiac deaths and HF deaths
occurred in patients who were LGE positive. The
study by O’Hanlon et al. (16) examined the signif-
icance of fibrosis detected by LGE on CMR for the
prediction of a combined primary clinical endpoint
(cardiovascular death, unplanned cardiovascular ad-
mission, sustained ventricular tachycardia or ven-
tricular fibrillation, or appropriate ICD discharge).
The LGE had a statistically significant associa-
tion with this combined primary endpoint (haz-
ard ratio of 3.4, p  0.006) (16). This study
showed a weak trend for predicting cardiovascu-
lar mortality (p  0.163) but was underpowered
for this endpoint. The study did not demonstrate
any difference in SCD as a function of the
presence of LGE (16).
The study by Bruder et al. (15) demonstrated
that LGE on CMR was significantly associated
with both all-cause mortality (OR: 5.47), and
cardiac mortality (OR: 8.01) (15); and LGE
emerged from multivariable analysis as an inde-
pendent predictor of mortality in HCM patients,
as LGE was present in 15 of the 16 patients who
had a significant cardiac event (sudden death,
Exclusion Pr
nting to
nter and
rt Institute
Signiﬁcant atherosclerotic
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myectomy
Occur
sym
dys
car
underwent
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SC
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374HF) (15). The extracted outcomes of interest for
this meta-analysis from these studies are pre-
sented in Table 3.
The meta-analysis shows that LGE was signifi-
cantly associated with cardiac death (pooled OR:
2.92, 95% CI: 1.01 to 8.42; p  0.047) (Fig. 2A)
over a mean follow-up of 3.1 years. Overall, 31 of
the 634 HCM patients with LGE on CMR had
cardiac death (4.9%), whereas only 5 of the 429
patients (1.2%) without LGE had cardiac death.
There was a trend toward an association between
LGE and sudden death/aborted sudden death (pooled
OR: 2.39, 95% CI: 0.87 to 6.58; p 0.091) (Fig. 2B).
The presence of LGE on CMR was associated with a
3.9% risk of sudden death/aborted death (25 of 634
subjects), but only 5 of the 429 subjects (1.2%)
without LGE experienced sudden death/aborted sud-
den death. The meta-analysis demonstrated a signif-
icant association between the presence of LGE and
HF death (pooled OR: 5.68, 95% CI: 1.04 to 31.07;
p 0.045) as 13 of 634 subjects (2.1%) with LGE on
CMR died of HF, but no patients without LGE on
CMR went on to die of HF (Fig. 2C). Although only
2 studies (Bruder et al. [15] and Rubinshtein et al.
[17] included data on all-cause mortality, the presence
of LGE was associated with all-cause mortality
(pooled OR: 4.46, 95% CI: 1.53 to 13.01; p 0.006)
(Fig. 2D). Table 4 summarizes the pooled OR for all
endpoints analyzed in this meta-analysis. The funnel
aracteristics of Included Primary Studies
(All) Male
Age,
yrs
NYHA
Functional
Class I
NYHA
Functional
Class II
NYHA
Function
Class III/
202 71% 42 17 61 31 19
424 59% 55 16 NR NR 125
217 71% 51.1 52 58 24
220 61% 58.0 3 43 17
,063 64% 52.4
or sum across all studies as appropriate for data.
ejection fraction; NYHA  New York Heart Association; NR  not reported; othe
diovascular Events by Study
llow-Up,
yrs Total, n LGE, n (%)
All-Cause
Mortality
All
D
LGE LGE LGE
1.9 202 111 (55) NR NR 2
3.6 424 239 (56) 9 2 6
3.1 217 136 (62) NR NR 8
3.0 220 148 (67) 20 2 15
3.1 1063 634 (60) 29 4 31
or sum across all studies as appropriate for data.
 late gadolinium enhancement; other abbreviations as in Tables 1 and 2.plot of effect size versus study precision demonstrated
no asymmetry to suggest major publication bias.
D I S C U S S I O N
This systematic review and meta-analysis demon-
strates that LGE on CMR is significantly associ-
ated with cardiac death, HF death, and all-cause
mortality in HCM, in addition to a trend toward an
association with sudden death/aborted sudden
death. These findings support the argument that
LGE on CMR should be considered as an inde-
pendent predictor of adverse cardiac outcomes in
HCM. The ability to more accurately predict which
HCM patients without current clinically accepted
risk factors are at high risk for developing cardiac
death, SCD, or HF death could have important
implications for the care of these patients. These
patients would be potentially identified for more
aggressive medical and device therapy than is cur-
rently clinically indicated (such as institution of
renin-aldosterone system inhibition for prevention
of HF or ICD placement for primary prevention of
SCD), and could potentially impact the morbidity
and mortality associated with HCM.
Elliott et al. (21) studied the use of traditional
noninvasive risk factors to identify high-risk HCM
patients that warrant ICD placement for primary
SCD prevention and followed up 368 patients (65%
LVEF, %
Wall
Thickness
>30 mm Syncope
Sustained
VT/VF
Family
History
of SCD
71 7 NR NR NR NR
67 9 NR NR NR NR
74 11 12 23 5 19
71 6 8 9 12 8
70 9
breviations as in Table 1.
diac
hs
SCD/Aborted
SCD SCD HF Death
LGE LGE LGE LGE LGE LGE LGE
3 4 3 2 3 0 0
0 8 0 4 0 2 0
1 3 1 1 1 6 0
1 10 1 8 1 5 0
5 25 5 15 5 13 0Table 2. Summary Ch
First Author
(Ref. #) n
al
IV
Maron (18)
Rubinshtein (17)
O’Hanlon (16)
Bruder (15)
Pooled 1
Pooled indicates averageTable 3. Adverse Car
First Author
(Ref. #)
Fo
Car
eat
Maron (18)
Rubinshtein (17)
O’Hanlon (16)
Bruder (15)
Pooled
Pooled indicates average
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375male) for an average of 3.6 2.5 years. Multivariate
SCD risk ratios for 5 of the traditional risk factors
ranged from 1.8 to 5.3, as patients without any of
the 5 risk factors had an estimated 6-year SCD-free
survival rate of 95%, while the presence of 1, 2, or
3 risk factors reduced the SCD-free survival rates to
93%, 82%, and 36%, respectively (21). They found
that patients with 2 or more traditional risk factors
had a lower 6-year SCD-free survival rate than
patients with only 1 or no risk factors, thus war-
ranting consideration for ICD therapy for primary
SCD prevention (21). This meta-analysis demon-
strates that LGE identified the chosen clinical end-
points with similar predictive accuracy (pooled OR
ranging from 1.45 to 2.92) as that of the traditional
noninvasive risk factors of Elliott et al. (21).
Study Odds Ratio(95% CI) p-va
Bruder   8.00   (1.04-61.87) 0.04
O’Hanlon   5.00   (0.61-40.73) 0.13
Maron   0.54   (0.08-3.29) 0.50
Rubinshtein 10.33  (0.58-184.51) 0.11
Pooled    2.92  (1.01-8.42) 0.04
A) Cardiac Death
Study Odds Ratio(95% CI) p-va
Bruder   5.15   (0.65-41.00) 0.11
O’Hanlon   1.81   (0.19-17.64) 0.61
Maron   1.10   (0.24-5.03) 0.90
Rubinshtein 13.62  (0.78-237.55) 0.07
Pooled    2.39  (0.87-6.58) 0.09
B) SCD/Aborted SCD
Study Odds Ratio(95% CI) p-va
Bruder    5.56   (0.30-101.90) 0.24
O’Hanlon   8.12   (0.45-146.04) 0.11
Rubinshtein   3.91  (0.19-81.83) 0.38
Pooled   5.68  (1.04-31.07) 0.04
 ) HF Death
Study Odds Ratio(95% CI) p-va
Bruder    5.47  (1.24-24.08) 0.02
Rubinshtein   3.58  (0.76-16.78) 0.10
Pooled   4.46  (1.53-13.01) 0.00
D) All Cause Mortality
      C
Figure 2. Forrest Plots and Pooled Odds Ratios for Clinical Endp
The presence of late gadolinium enhancement by cardiac magnetic
and (D) all-cause mortality. Additionally, there was a trend toward s
SCD. CI  conﬁdence interval.
Table 4. Adverse Cardiovascular Events Pooled Odds Ratios
Adverse Cardiovascular
Events Pooled OR 95% CI p Value
Cardiac death 2.92 1.01–8.42 0.047
SCD/aborted SCD 2.39 0.87–6.58 0.091
SCD 1.45 0.47–4.52 0.519
HF death 5.68 1.04–31.07 0.045
All-cause mortality 4.46 1.53–13.01 0.006
CI  conﬁdence interval; OR  odds ratio; other abbreviations as in Tables 1
and 3.This meta-analysis has several limitations. First,
there have only been a small number of clinical
studies that have analyzed the ability of LGE by
CMR to identify the clinically relevant endpoints of
SCD, HF death, and cardiovascular mortality, and
therefore, the total number of patients evaluated
remains small and is reflected by the width of the
pooled OR confidence intervals. While showing a
trend toward the detection of SCD/aborted SCD,
this meta-analysis is still underpowered to demon-
strate the ability of LGE to predict this important
outcome. Second, studies have only included sub-
jects who have not had a prior ICD placement
because of the incompatibility of these devices with
magnetic resonance imaging. That has biased these
clinical studies toward subjects who have fewer risk
factors and potentially lower events of SCD, as
most of the patients typically have not met criteria
for ICD placement previously. Ideally, CMR would
be performed at the time of diagnosis so that LGE
could be assessed in all patients regardless of their
number of traditional risk factors. On the basis of
limitations provided by the raw data, we were
unable to calculate adjusted OR taking into account
the traditional risk factors. Another key limitation
is the ability to control for ICD prescription after
0.01 0.1 1 10 100
0.01 0.1 1 10 100
0.01 0.1 1 10 100
0.01 0.1 1 10 100
ts
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376heterogeneity in prescribing practices between the
studies’ respective centers. The ICDs would likely
decrease the incidence of cardiovascular death and
SCD, but would not be expected to effect the com-
bined endpoint of SCD/aborted SCD as device inter-
rogation would identify patients with aborted SCD.
The current literature evaluating LGE by CMR
has mostly classified the presence or absence of
LGE as a binary variable. The high incidence of
LGE in HCM seen in this meta-analysis (60%
of patients) necessitates the development more
sophisticated techniques for quantifying LGE in
HCM to potentially improve the prognostic utility
of these techniques (20). Approaches may include
using a standardized semiquantitative scoring of
LGE utilizing a 17-segment approach (similar to
the sum rest score used in nuclear perfusion studies)
to quantify overall scar burden. Further investiga-
tion to better characterize the implications of the
level of LGE present could potentially lead to
greater specificity with regard to using LGE to
predict outcomes. Additional CMR parameters
such as the total scar burden and scar surface area by
quantitative analysis might also improve the detec-
tion of clinically significant LGE identified on
CMR. Previous work by Bello et al. (22) in CAD
has shown that once infarct mass is 10% of LV
ass, the risk for death increases 2-fold, and pa-
ients with 24% scar were at an even higher risk.
nfarct surface area and mass have been identified as
tronger predictors of risk for monomorphic ven-
ricular arrhythmias than reduced LVEF in patients
ith coronary artery disease (23). The ongoing
ETERMINE (Defibrillators to Reduce Risk by
agnetic Resonance Imaging Evaluation) trial will
valuate ICD therapy in patients with ischemic car-
iomyopathy with mild-moderate systolic LV dys-
unction (LVEF 35% to 50%) and scar burden of
10% of LV mass (24), potentially offering insight
nto whether ICD discharge correlates with total scar
urden and scar surface area. This threshold effect of
car may also have implications in HCM. The ability
o accurately access total scar burden through T1
apping could provide a more objective method of
oninvasively quantifying diffuse myocardial fibrosis,
s recent studies have validated this method in various
yocardial diseases (25,26). Additionally, stress per-
usion CMR could also be used in HCM to further
tratify the risk for SCD. Several studies have looked
t single-photon emission computed tomography and
ts relation to ischemia in HCM, as Sorajja et al. (27)
ound that ischemia identified by single-photon emis-ion computed tomography in adult HCM patients
average age 60  16 years) was significantly associ-
ted with cardiovascular death. The ability of CMR to
ccurately quantify the extent and severity of ventric-
lar hypertrophy, identify and quantify scar (using
GE or T1 mapping) while also evaluating for induc-
ble ischemia may provide clinicians with a more
ccurate appraisal of a patient’s risk for SCD and other
dverse cardiovascular outcomes than traditional risk
actors may indicate. An algorithm utilizing various
MR parameters may improve the predictive value in
dentifying patients that may benefit from ICD place-
ent or other primary prevention strategies.
As previously proposed (20), a large, prospective
egistry using a multicenter approach would help to
efinitively establish LGE and other CMR param-
ters as a predictor of SCD and cardiac death in
CM. This registry could include various CMR
arameters in addition to the assessment of traditional
linical risk factors. The goal of this registry would be
o determine whether CMR-derived risk factors pro-
ide independent prognostic value over current clinical
isk factors for predicting adverse clinical outcomes
uch as SCD or cardiac death. Although the currently
vailable data clearly show a trend toward an associa-
ion between LGE and SCD/aborted SCD, the
ooled data are still underpowered for detecting this
mportant endpoint and are limited with regard to
bility to properly control for traditional risk factors.
he ongoing European CMR registry is prospectively
valuating the utility of CMR for risk stratification in
CM patients (28). This registry, as well as a pro-
osed international CMR registry focused on HCM
hat is being planned, will provide additional statistical
ower to definitively address the utility of LGE for
redicting SCD.
C O N C L U S I O N S
Overall, LGE on CMR appears to possess signifi-
cant prognostic power in the prediction of serious
cardiac complications in HCM (all-cause mortality,
cardiac death, and HF death). Using several CMR
parameters may increase the positive predictive
value of CMR in identifying patients who should be
candidates for a more aggressive treatment ap-
proach than is current clinical practice.
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